Enter drug's generic or brand name below. Results will appear here. Note: all drug related information obtained on this page is provided by RX List.
Using the RX LIST database:
(1) Enter the drug name in the search box below and hit ENTER
(2) The rx list web site will open here with the drug search completed. Next, scroll down the page to locate the link to the drug you are searching for and then click on the link.
Fluzone Quadrivalent
(Influenza Vaccine)
for Intramuscular Injection
Fluzone Quadrivalent (Influenza Vaccine) for intramuscular injection is an inactivated influenza vaccine, prepared from influenza viruses propagated in embryonated chicken eggs. The viruscontaining allantoic fluid is harvested and inactivated with formaldehyde. Influenza virus is concentrated and purified in a linear sucrose density gradient solution using a continuous flow centrifuge. The virus is then chemically disrupted using a non-ionic surfactant, octylphenol ethoxylate (Triton® X-100), producing a “split virus”. The split virus is further purified and then suspended in sodium phosphate-buffered isotonic sodium chloride solution. The Fluzone Quadrivalent process uses an additional concentration factor after the ultrafiltration step in order to obtain a higher hemagglutinin (HA) antigen concentration. Antigens from the four strains included in the vaccine are produced separately and then combined to make the quadrivalent formulation.
Fluzone Quadrivalent suspension for injection is clear and slightly opalescent in color.
Antibiotics are not used in the manufacture of Fluzone Quadrivalent.
The Fluzone Quadrivalent prefilled syringe and vial presentations are not made with natural rubber latex.
Fluzone Quadrivalent is standardized according to United States Public Health Service requirements and is formulated to contain HA of each of the following four influenza strains recommended for the 2016-2017 influenza season: A/California/07/2009 X-179A (H1N1), A/Hong Kong/4801/2014 X-263B (H3N2), B/Phuket/3073/2013 (B Yamagata lineage), and B/Brisbane/60/2008 (B Victoria lineage). The amounts of HA and other ingredients per dose of vaccine are listed in Table 6. The single-dose, pre-filled syringe (0.25 mL and 0.5 mL) and the single-dose vial (0.5 mL) are manufactured and formulated without thimerosal or any other preservative. The 5 mL multi-dose vial presentation contains thimerosal, a mercury derivative, added as a preservative. Each 0.5 mL dose from the multi-dose vial contains 25 mcg mercury. Each 0.25 mL dose from the multi-dose vial contains 12.5 mcg mercury.
Table 6: Fluzone Quadrivalent Ingredients
| Ingredient | Quantity (per dose) | |
| Fluzone Quadrivalent 0.25 mL Dose | Fluzone Quadrivalent 0.5 mL Dose | |
| Active Substance: Split influenza virus, inactivated strainsa: | 30 mcg HA total | 60 mcg HA total |
| A (H1N1) | 7.5 mcg HA | 15 mcg HA |
| A (H3N2) | 7.5 mcg HA | 15 mcg HA |
| B/(Victoria lineage) | 7.5 mcg HA | 15 mcg HA |
| B/(Yamagata lineage) | 7.5 mcg HA | 15 mcg HA |
| Other: | ||
| Sodium phosphate-buffered isotonic | QSb to appropriate | QSb to appropriate |
| sodium chloride solution | volume | volume |
| Formaldehyde | ≤ 50 mcg | ≤ 100 mcg |
| Octylphenol ethoxylate | ≤ 125 mcg | ≤ 250 mcg |
| Preservative | ||
| Single-dose presentations | - | - |
| Multi-dose presentation (thimerosal) | 12.5 mcg mercury | 25 mcg mercury |
| aper United States Public Health Service
(USPHS) requirement bQuantity Sufficient “-” Indicates information is not applicable |
||
Fluzone® Quadrivalent is a vaccine indicated for active immunization for the prevention of influenza disease caused by influenza A subtype viruses and type B viruses contained in the vaccine.
Fluzone Quadrivalent is approved for use in persons 6 months of age and older.
The dose and schedule for Fluzone Quadrivalent are presented in Table 1.
Table 1: Dose and Schedule for Fluzone Quadrivalent
| Age | Dose | Schedule |
| 6 months through 35 months | One or two dosesa , 0.25 mL each | If 2 doses, administer at least 4 weeks apart |
| 36 months through 8 years | One or two dosesa , 0.5 mL each | If 2 doses, administer at least 4 weeks apart |
| 9 years and older | One dose, 0.5 mL | - |
| a1 or 2 doses depends on vaccination history
as per Advisory Committee on Immunization Practices annual recommendations on prevention and control of influenza with vaccines “-” Indicates information is not applicable |
||
Parenteral drug products should be inspected visually for particulate matter and/or discoloration prior to administration, whenever solution and container permit. If any of these defects or conditions exist, Fluzone Quadrivalent should not be administered.
Before administering a dose of vaccine, shake the prefilled syringe or vial. Withdraw one dose of vaccine from the single-dose vial using a sterile needle and syringe. Use a separate sterile needle and syringe for each dose withdrawn from the multi-dose vial.
The preferred sites for intramuscular injection are the anterolateral aspect of the thigh in infants 6 months through 11 months of age, the anterolateral aspect of the thigh (or the deltoid muscle if muscle mass is adequate) in persons 12 months through 35 months of age, or the deltoid muscle in persons ≥ 36 months of age. The vaccine should not be injected into the gluteal area or areas where there may be a major nerve trunk.
Do not administer this product intravenously, intradermally, or subcutaneously.
Fluzone Quadrivalent should not be combined through reconstitution or mixed with any other vaccine.
Fluzone Quadrivalent is a suspension for injection.
Fluzone Quadrivalent is supplied in 4 presentations:
Single-dose, prefilled syringe (pink plunger rod), without needle, 0.25 mL (NDC 49281-516-00) (not made with natural rubber latex). Supplied as package of 10 (NDC 49281- 516-25).
Single-dose, prefilled syringe (clear plunger rod), without needle, 0.5 mL (NDC 49281-416-88 ) (not made with natural rubber latex). Supplied as package of 10 (NDC 49281-416-50
Single-dose vial, 0.5 mL (NDC 49281-416-58) (not made with natural rubber latex). Supplied as package of 10 (NDC 49281-416-10).
Multi-dose vial, 5 mL (NDC 49281-625-78) (not made with natural rubber latex). Supplied as package of 1 (NDC 49281- 625-15). A maximum of ten doses can be withdrawn from the multidose vial.
Store all Fluzone Quadrivalent presentations refrigerated at 2° to 8°C (35° to 46°F). DO NOT FREEZE. Discard if vaccine has been frozen.
Do not use after the expiration date shown on the label.
Manufactured by: Sanofi Pasteur Inc. Swiftwater PA 18370 USA. Revised: Jun 2016
In children 6 months through 35 months of age, the most common ( ≥ 10%) injection-site reactions were pain (57%)a or tenderness (54%)b, erythema (37%), and swelling (22%); the most common solicited systemic adverse reactions were irritability (54%)b, abnormal crying (41%)b, malaise (38%)a, drowsiness (38%)b, appetite loss (32%)b, myalgia (27%)a, vomiting (15%)b, and fever (14%). In children 3 years through 8 years of age, the most common ( ≥ 10%) injection-site reactions were pain (67%), erythema (34%), and swelling (25%); the most common solicited systemic adverse reactions were myalgia (39%), malaise (32%), and headache (23%). In adults 18 years and older, the most common ( ≥ 10%) injection-site reaction was pain (47%); the most common solicited systemic adverse reactions were myalgia (24%), Â headache (16%), and malaise (11%). In adults 65 years of age and older, the most common ( ≥ 10%) injection-site reaction was pain (33%); the most common solicited systemic adverse reactions were myalgia (18%), headache (13%), and malaise (11%).
Because clinical trials are conducted under widely varying conditions, adverse event rates observed in the clinical trial(s) of a vaccine cannot be directly compared to rates in the clinical trial(s) of another vaccine and may not reflect the rates observed in practice.
Study 1 (NCT01240746, see http://clinicaltrials.gov) was a single-blind, randomized, activecontrolled multi-center safety and immunogenicity study conducted in the US. In this study, children 6 months through 35 months of age received one or two 0.25 mL doses of either Fluzone Quadrivalent or one of two formulations of a comparator trivalent influenza vaccine (TIV-1 or TIV-2), and children 3 years through 8 years of age received one or two 0.5 mL doses of either Fluzone Quadrivalent, TIV-1, or TIV-2. Each of the trivalent formulations contained an influenza type B virus that corresponded to one of the two type B viruses in Fluzone Quadrivalent (a type B virus of the Victoria lineage or a type B virus of the Yamagata lineage). For participants who received two doses, the doses were administered approximately 4 weeks apart. The safety analysis set included 1841 children 6 months through 35 months of age and 2506 children 3 years through 8 years of age. Among participants 6 months through 8 years of age in the three vaccine groups combined, 49.3% were female (Fluzone Quadrivalent, 49.2%; TIV-1, 49.8%; TIV-2, 49.4%), 58.4% Caucasian (Fluzone Quadrivalent, 58.4%; TIV-1, 58.9%; TIV-2, 57.8%), 20.2% Black (Fluzone Quadrivalent, 20.5%; TIV-1, 19.9%; TIV-2, 19.1%), 14.1% Hispanic (Fluzone Quadrivalent, 14.3%; TIV-1, 13.2%; TIV-2, 14.7%), and 7.3% were of other racial/ethnic groups (Fluzone Quadrivalent, 6.8%; TIV-1, 8.0%; TIV-2, 8.5%). Table 2 and Table 3 summarize solicited injection-site and systemic adverse reactions reported within 7 days post-vaccination via diary cards. Participants were monitored for unsolicited adverse events for 28 days after each dose and serious adverse events (SAEs) during the 6 months following the last dose.
Table 2: Study 1a: Percentage of Solicited
Injection-site and Systemic Adverse Reactions Within 7 Days After Vaccination
in Children 6 Months Through 35 Months of Age (Safety Analysis Set)b
| Fluzone Quadrivalentc (Nf=1223) |
TIV-1d (B Victoria) (Nf=310) |
TIV-2e (B Yamagata) (Nf=308) |
|||||||
| Any (%) | Grade 2g (%) | Grade 3h (%) | Any (%) | Grade 2g (%) | Grade 3h (%) | Any (%) | Grade 2g (%) | Grade 3h (%) | |
| Injection-site adverse reactions | |||||||||
| Paini | 57.0 | 10.2 | 1.0 | 52.3 | 11.5 | 0.8 | 50.3 | 5.4 | 2.7 |
| Tendernessj | 54.1 | 11.3 | 1.9 | 48.4 | 8.2 | 1.9 | 49.7 | 10.3 | 0.0 |
| Erythema | 37.3 | 1.5 | 0.2 | 32.9 | 1.0 | 0.0 | 33.3 | 1.0 | 0.0 |
| Swelling | 21.6 | 0.8 | 0.2 | 19.7 | 1.0 | 0.0 | 17.3 | 0.0 | 0.0 |
| Systemic adverse reactions | |||||||||
| Fever ( ≥ 100.4°F)k | 14.3 | 5.5 | 2.1 | 16.0 | 6.6 | 1.7 | 13.0 | 4.1 | 2.0 |
| Malaisei | 38.1 | 14.5 | 4.6 | 35.2 | 14.8 | 4.7 | 32.4 | 12.8 | 6.8 |
| Myalgiai | 26.7 | 6.6 | 1.9 | 26.6 | 9.4 | 1.6 | 25.0 | 6.8 | 2.7 |
| Headachei | 8.9 | 2.5 | 0.6 | 9.4 | 3.9 | 0.0 | 12.2 | 4.7 | 0.0 |
| Irritabilitvi | 54.0 | 26.4 | 3.2 | 52.8 | 20.1 | 3.1 | 53.5 | 22.9 | 2.8 |
| Crying abnormalj | 41.2 | 12.3 | 3.3 | 36.5 | 8.2 | 1.9 | 29.9 | 10.4 | 2.1 |
| Drowsinessj | 37.7 | 8.4 | 1.3 | 32.1 | 3.8 | 0.6 | 31.9 | 5.6 | 0.7 |
| Appetite lossj | 32.3 | 9.1 | 1.8 | 33.3 | 5.7 | 1.9 | 25.0 | 8.3 | 0.7 |
| Vomitingj | 14.8 | 6.2 | 1.0 | 11.3 | 4.4 | 0.6 | 13.9 | 6.3 | 0.0 |
| aNCT01240746 bThe safety analysis set includes all persons who received at least one dose of study vaccine cFluzone Quadrivalent containing A/California/07/2009 (H1N1), A/Victoria/210/2009 (H3N2), B/Brisbane/60/2008 (Victoria lineage), and B/Florida/04/2006 (Yamagata lineage) d2010-2011 Fluzone TIV containing A/California/07/2009 (H1N1), A/Victoria/210/2009 (H3N2), and B/Brisbane/60/2008 (Victoria lineage), licensed eInvestigational TIV containing A/California/07/2009 (H1N1), A/Victoria/210/2009 (H3N2), and B/Florida/04/2006 (Yamagata lineage), non-licensed fN is the number of participants in the safety analysis set gGrade 2 - Injection-site pain: sufficiently discomforting to interfere with normal behavior or activities; Injection-site tenderness: cries and protests when injection-site is touched; Injectionsite erythema, Injection-site swelling: ≥ 2.5 cm to < 5 cm; Fever: > 101.3°F to ≤ 103.1°F (6 months through 23 months); ≥ 101.2°F to ≤ 102.0°F (24 months through 35 months); Malaise, Myalgia, and Headache: some interference with activity; Irritability: requiring increased attention; Crying abnormal: 1 to 3 hours; Drowsiness: not interested in surroundings or did not wake up for a feed/meal; Appetite loss: missed 1 or 2 feeds/meals completely; Vomiting: 2 to 5 episodes per 24 hours hGrade 3 - Injection-site pain: incapacitating, unable to perform usual activities; Injection-site tenderness: cries when injected limb is moved, or the movement of the injected limb is reduced; Injection-site erythema, Injection-site swelling: ≥ 5 cm; Fever: > 103.1°F (6 months through 23 months); ≥ 102.1°F (24 months through 35 months); Malaise, Myalgia, and Headache: Significant; prevents daily activity; Irritability: inconsolable; Crying abnormal: > 3 hours; Drowsiness: sleeping most of the time or difficult to wake up; Appetite loss: refuses ≥ 3 feeds/ meals or refuses most feeds/meals; Vomiting: ≥ 6 episodes per 24 hours or requiring parenteral hydration iAssessed in children 24 months through 35 months of age jAssessed in children 6 months through 23 months of age kFever measured by any route |
|||||||||
Table 3: Study 1a: Percentage of Solicited
Injection-site and Systemic Adverse Reactions Within 7 Days After Vaccination
in Children 3 Years Through 8 Years of Age (Safety Analysis Set)b
| Fluzone Quadrivalentc (Nf=1669) |
TIV-1d (B Victoria) (Nf=424) |
TIV-2e (B Yamagata) (Nf=413) |
|||||||
| Any (%) | Grade 2g (%) | Grade 3h (%) | Any (%) | Grade 2g (%) | Grade 3h (%) | Any (%) | Grade 2g (%) | Grade 3h (%) | |
| Injection-site adverse reactions | |||||||||
| Pain | 66.6 | 15.8 | 2.1 | 64.6 | 9.5 | 2.0 | 63.8 | 11.6 | 2.8 |
| Erythema | 34.1 | 2.9 | 1.8 | 36.8 | 3.4 | 1.2 | 35.2 | 2.5 | 1.8 |
| Swelling | 24.8 | 2.8 | 1.4 | 25.4 | 1.5 | 1.2 | 25.9 | 2.5 | 1.8 |
| Systemic adverse reactions | |||||||||
| Fever ( ≥ 100.4°F)i | 7.0 | 2.1 | 2.1 | 7.1 | 2.2 | 1.2 | 7.6 | 2.8 | 0.8 |
| Headache | 23.1 | 6.8 | 2.2 | 21.2 | 5.1 | 2.7 | 24.4 | 7.5 | 2.0 |
| Malaise | 31.9 | 11.2 | 5.5 | 32.8 | 11.4 | 5.6 | 33.4 | 10.8 | 5.0 |
| Myalgia | 38.6 | 12.2 | 3.3 | 34.1 | 9.0 | 2.7 | 38.4 | 11.1 | 2.8 |
| aNCT01240746 bThe safety analysis set includes all persons who received at least one dose of study vaccine cFluzone Quadrivalent containing A/California/07/2009 (H1N1), A/Victoria/210/2009 (H3N2), B/ Brisbane/60/2008 (Victoria lineage), and B/Florida/04/2006 (Yamagata lineage) d2010-2011 Fluzone TIV containing A/California/07/2009 (H1N1), A/Victoria/210/2009 (H3N2), and B/Brisbane/60/2008 (Victoria lineage), licensed eInvestigational TIV containing A/California/07/2009 (H1N1), A/Victoria/210/2009 (H3N2), and B/Florida/04/2006 (Yamagata lineage), non-licensed fN is the number of participants in the safety analysis set gGrade 2 - Injection-site pain: sufficiently discomforting to interfere with normal behavior or activities; Injection-site erythema, Injection-site swelling: ≥ 2.5 cm to < 5 cm; Fever: ≥ 101.2°F to ≤ 102.0°F; Headache, Malaise, and Myalgia: some interference with activity hGrade 3 - Injection-site pain: incapacitating, unable to perform usual activities; Injection-site erythema, Injection-site swelling: ≥ 5 cm; Fever: ≥ 102.1°F; Headache, Malaise, and Myalgia: Significant; prevents daily activity iFever measured by any route |
|||||||||
Among children 6 months through 8 years of age, unsolicited non-serious adverse events were reported in 1360 (47.0%) recipients in the Fluzone Quadrivalent group, 352 (48.0%) recipients in the TIV-1 group, and 346 (48.0%) recipients in the TIV-2 group. The most commonly reported unsolicited non-serious adverse events were cough, vomiting, and pyrexia. During the 28 days following vaccination, a total of 16 (0.6%) recipients in the Fluzone Quadrivalent group, 4 (0.5%) recipients in the TIV-1 group, and 4 (0.6%) recipients in the TIV-2 group, experienced at least one SAE; no deaths occurred. Throughout the study period, a total of 41 (1.4%) recipients in the Fluzone Quadrivalent group, 7 (1.0%) recipients in the TIV-1 group, and 14 (1.9%) recipients in the TIV-2 group, experienced at least one SAE. Three SAEs were considered to be possibly related to vaccination: croup in a Fluzone Quadrivalent recipient and 2 episodes of febrile seizure, 1 each in a TIV-1 recipient and a TIV-2 recipient. One death occurred in the TIV-1 group (a drowning 43 days post-vaccination).
In study 2 (NCT00988143, see http://clinicaltrials.gov), a multi-centered randomized, open-label trial conducted in the US, adults 18 years of age and older received one dose of either Fluzone Quadrivalent or one of two formulations of comparator trivalent influenza vaccine (TIV-1 or TIV-2). Each of the trivalent formulations contained an influenza type B virus that corresponded to one of the two type B viruses in Fluzone Quadrivalent (a type B virus of the Victoria lineage or a type B virus of the Yamagata lineage). The safety analysis set included 570 recipients, half aged 18-60 years and half aged 61 years or older. Among participants in the three vaccine groups combined, 67.2% were female (Fluzone Quadrivalent, 68.4%; TIV-1, 67.9%; TIV-2, 65.3%), 88.4% Caucasian (Fluzone Quadrivalent, 91.1%; TIV-1, 86.8%; TIV-2, 87.4%), 9.6% Black (Fluzone Quadrivalent, 6.8%; TIV-1, 12.1%; TIV-2, 10.0%), 0.4% Hispanic (Fluzone Quadrivalent, 0.0%; TIV-1, 0.5%; TIV-2, 0.5%), and 1.7% were of other racial/ethnic groups (Fluzone Quadrivalent, 2.1%; TIV-1, 0.5%; TIV-2, 2.2%). Table 4 summarizes solicited injection-site and systemic adverse reactions reported within 3 days post-vaccination via diary cards. Participants were monitored for unsolicited adverse events and SAEs during the 21 days following vaccination.
Table 4: Study 2a: Percentage of Solicited
Injection-site and Systemic Adverse Reactions Within 3 Days After Vaccination
in Adults 18 Years of Age and Older (Safety Analysis Set)b
| Fluzone Quadrivalentc (Nf=190) |
TIV-1d (B Victoria) (Nf=190) |
TIV-2e (B Yamagata) (Nf=190) |
|||||||
| Any (%) | Grade 2g (%) | Grade 3h (%) | Any (%) | Grade 2g (%) | Grade 3h (%) | Any (%) | Grade 2g (%) | Grade 3h (%) | |
| Injection-site adverse reactions | |||||||||
| Pain | 47.4 | 6.8 | 0.5 | 52.1 | 7.9 | 0.5 | 43.2 | 6.3 | 0.0 |
| Erythema | 1.1 | 0.0 | 0.0 | 1.6 | 0.5 | 0.0 | 1.6 | 0.5 | 0.0 |
| Swelling | 0.5 | 0.0 | 0.0 | 3.2 | 0.5 | 0.0 | 1.1 | 0.0 | 0.0 |
| Induration | 0.5 | 0.0 | 0.0 | 1.6 | 0.5 | 0.0 | 0.5 | 0.0 | 0.0 |
| Ecchymosis | 0.5 | 0.0 | 0.0 | 0.5 | 0.0 | 0.0 | 0.5 | 0.0 | 0.0 |
| Systemic adverse reactions | |||||||||
| Myalgia | 23.7 | 5.8 | 0.0 | 25.3 | 5.8 | 0.0 | 16.8 | 5.8 | 0.0 |
| Headache | 15.8 | 3.2 | 0.5 | 18.4 | 6.3 | 0.5 | 18.0 | 4.2 | 0.0 |
| Malaise | 10.5 | 1.6 | 1.1 | 14.7 | 3.2 | 1.1 | 12.1 | 4.7 | 0.5 |
| Shivering | 2.6 | 0.5 | 0.0 | 5.3 | 1.1 | 0.0 | 3.2 | 0.5 | 0.0 |
| Fever ( ≥ 100.4°F)i | 0.0 | 0.0 | 0.0 | 0.5 | 0.5 | 0.0 | 0.5 | 0.5 | 0.0 |
| aNCT00988143 bThe safety analysis set includes all persons who received study vaccine cFluzone Quadrivalent containing A/California/07/2009 (H1N1), A/Victoria/210/2009 (H3N2), B/Brisbane/60/2008 (Victoria lineage), and B/Florida/04/2006 (Yamagata lineage) d2009-2010 Fluzone TIV containing A/Brisbane/59/2007 (H1N1), A/Uruguay/716/2007 (H3N2), and B/Brisbane/60/2008 (Victoria lineage), licensed e2008-2009 Fluzone TIV containing A/Brisbane/59/2007 (H1N1), A/Uruguay/716/2007 (H3N2), and B/Florida/04/2006 (Yamagata lineage), licensed fN is the number of participants in the safety analysis set gGrade 2 - Injection-site pain: Some interference with activity; Injection-site erythema, Injectionsite swelling, Injection-site induration, and Injection-site ecchymosis: ≥ 5.1 to ≤ 10 cm; Fever: ≥ 101.2°F to ≤ 102.0°F; Myalgia, Headache, Malaise, and Shivering: some interference with activity hGrade 3 - Injection-site pain: Significant; prevents daily activity; Injection-site erythema, Injection-site swelling, Injection-site induration, and Injection-site ecchymosis: > 10 cm; Fever: ≥ 102.1°F; Myalgia, Headache, Malaise, and Shivering: Significant; prevents daily activity iFever measured by any route |
|||||||||
Unsolicited non-serious adverse events were reported in 33 (17.4%) recipients in the Fluzone Quadrivalent group, 45 (23.7%) recipients in the TIV-1 group, and 45 (23.7%) recipients in the TIV-2 group. The most commonly reported unsolicited non-serious adverse events were headache, cough, and oropharyngeal pain. In the follow-up period, there were two SAEs, 1 (0.5%) in the Fluzone Quadrivalent group and 1 (0.5%) in the TIV-2 group. No deaths were reported during the trial period.
In Study 3 (NCT01218646, see http://clinicaltrials.gov), a multi-center, randomized, double-blind trial conducted in the US, adults 65 years of age and older received one dose of either Fluzone Quadrivalent, or one of two formulations of comparator trivalent influenza vaccine (TIV-1 or TIV- 2). Each of the trivalent formulations contained an influenza type B virus that corresponded to one of the two type B viruses in Fluzone Quadrivalent (a type B virus of the Victoria lineage or a type B virus of the Yamagata lineage). The safety analysis set included 675 recipients. Among participants in the three vaccine groups combined, 55.7% were female (Fluzone Quadrivalent, 57.3%; TIV-1, 56.0%; TIV-2, 53.8%), 89.5% Caucasian (Fluzone Quadrivalent, 87.6%; TIV-1, 89.8%; TIV-2, 91.1%), 2.2% Black (Fluzone Quadrivalent, 4.0%; TIV-1, 1.8%; TIV-2, 0.9%), 7.4% Hispanic (Fluzone Quadrivalent, 8.4%; TIV-1, 7.6%; TIV-2, 6.2%) and 0.9% were of other racial/ ethnic groups (Fluzone Quadrivalent, 0.0%; TIV-1, 0.9%; TIV-2, 1.8%).
Table 5 summarizes solicited injection-site and systemic adverse reactions reported within 7 days post-vaccination via diary cards. Participants were monitored for unsolicited adverse events and SAEs during the 21 days following vaccination.
Table 5: Study 3a: Percentage of Solicited
Injection-site and Systemic Adverse Reactions Within 7 Days After Vaccination in
Adults 65 Years of Age and Older (Safety Analysis Set)b
| Fluzone Quadrivalentc (Nf=225) |
TIV-1d (B Victoria) (Nf=225) |
TIV-2e (B Yamagata) (Nf=225) |
|||||||
| Any (%) | Grade 2g (%) | Grade 3h (%) | Any (%) | Grade 2g (%) | Grade 3h (%) | Any (%) | Grade 2g (%) | Grade 3h (%) | |
| Injection-site adverse reactions | |||||||||
| Pain | 32.6 | 1.3 | 0.9 | 28.6 | 2.7 | 0.0 | 23.1 | 0.9 | 0.0 |
| Erythema | 2.7 | 0.9 | 0.0 | 1.3 | 0.0 | 0.0 | 1.3 | 0.4 | 0.0 |
| Swelling | 1.8 | 0.4 | 0.0 | 1.3 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Systemic adverse reactions | |||||||||
| Myalgia | 18.3 | 4.0 | 0.4 | 18.3 | 4.0 | 0.0 | 14.2 | 2.7 | 0.4 |
| Headache | 13.4 | 1.3 | 0.4 | 11.6 | 1.3 | 0.0 | 11.6 | 1.8 | 0.4 |
| Malaise | 10.7 | 4.5 | 0.4 | 6.3 | 0.4 | 0.0 | 11.6 | 2.7 | 0.9 |
| Fever ( ≥ 100.4°F)i | 1.3 | 0.0 | 0.4 | 0.0 | 0.0 | 0.0 | 0.9 | 0.4 | 0.4 |
| aNCT01218646 bThe safety analysis set includes all persons who received study vaccine cFluzone Quadrivalent containing A/California/07/2009 (H1N1), A/Victoria/210/2009 (H3N2), B/Brisbane/60/2008 (Victoria lineage), and B/Florida/04/2006 (Yamagata lineage) d2010-2011 Fluzone TIV containing A/California/07/2009 (H1N1), A/Victoria/210/2009 (H3N2), and B/Brisbane/60/2008 (Victoria lineage), licensed eInvestigational TIV containing A/California/07/2009 (H1N1), A/Victoria/210/2009 (H3N2), and B/Florida/04/2006 (Yamagata lineage), non-licensed fN is the number of participants in the safety analysis set gGrade 2 - Injection-site pain: some interference with activity; Injection-site erythema and Injection-site swelling: ≥ 5.1 to ≤ 10 cm; Fever: ≥ 101.2°F to ≤ 102.0°F; Myalgia, Headache, and Malaise: some interference with activity hGrade 3 - Injection-site pain: Significant; prevents daily activity; Injection-site erythema and Injection-site swelling: > 10 cm; Fever: ≥ 102.1°F; Myalgia, Headache, and Malaise: Significant; prevents daily activity iFever measured by any route |
|||||||||
Unsolicited non-serious adverse events were reported in 28 (12.4%) recipients in the Fluzone Quadrivalent group, 22 (9.8%) recipients in the TIV-1 group, and 22 (9.8%) recipients in the TIV- 2 group. The most commonly reported adverse events were oropharyngeal pain, rhinorrhea, injection-site induration, and headache. Three SAEs were reported during the follow-up period, 2 (0.9%) in the TIV-1 group and 1 (0.4%) in the TIV-2 group. No deaths were reported during the trial period.
Currently, there are no post-marketing data available for Fluzone Quadrivalent vaccine.
The following events have been spontaneously reported during the post-approval use of the trivalent formulation of Fluzone. Because these events are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to vaccine exposure. Adverse events were included based on one or more of the following factors: severity, frequency of reporting, or strength of evidence for a causal relationship to Fluzone.
No information provided.
a Assessed in children 24 months through 35 months of age
b Assessed in children 6 months through 23 months of age
Included as part of the PRECAUTIONS section.
The 1976 swine influenza vaccine was associated with an elevated risk of Guillain-Barré syndrome (GBS). Evidence for a causal relation of GBS with other influenza vaccines is inconclusive; if an excess risk exists, it is probably slightly more than 1 additional case per 1 million persons vaccinated. (See ref. 1) If GBS has occurred within 6 weeks following previous influenza vaccination, the decision to give Fluzone Quadrivalent should be based on careful consideration of the potential benefits and risks.
Appropriate medical treatment and supervision must be available to manage possible anaphylactic reactions following administration of Fluzone Quadrivalent.
If Fluzone Quadrivalent is administered to immunocompromised persons, including those receiving immunosuppressive therapy, the expected immune response may not be obtained.
Vaccination with Fluzone Quadrivalent may not protect all recipients.
See FDA-approved patient labeling (PATIENT INFORMATION). Inform the vaccine recipient or guardian:
Vaccine Information Statements must be provided to vaccine recipients or their guardians, as required by the National Childhood Vaccine Injury Act of 1986 prior to immunization. These materials are available free of charge at the Centers for Disease Control and Prevention (CDC) website (www.cdc.gov/vaccines).
Fluzone Quadrivalent has not been evaluated for carcinogenic or mutagenic potential. A reproductive study of female rabbits vaccinated with Fluzone Quadrivalent was performed and revealed no evidence of impaired female fertility [see Pregnancy].
Pregnancy Category B: A developmental and reproductive toxicity study has been performed in female rabbits at a dose approximately 20 times the human dose (on a mg/kg basis) and has revealed no evidence of impaired female fertility or harm to the fetus due to Fluzone Quadrivalent. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, Fluzone Quadrivalent should be given to a pregnant woman only if clearly needed.
In the developmental and reproductive toxicity study, female rabbits were administered Fluzone Quadrivalent or control saline (each 0.5 mL/dose) by intramuscular injection 24 and 10 days before insemination, and on Days 6, 12, and 27 of gestation. The administration of Fluzone Quadrivalent did not result in systemic maternal toxicity (no adverse clinical signs and no change in body weight or food consumption). In addition, no adverse effects on pregnancy, parturition, lactation, or embryo-fetal or pre-weaning development were observed. There were no vaccine-related fetal malformations or other evidence of teratogenesis noted in this study.
Sanofi Pasteur Inc. is maintaining a prospective pregnancy exposure registry to collect data on pregnancy outcomes and newborn health status following vaccination with Fluzone Quadrivalent during pregnancy. Healthcare providers are encouraged to enroll women who receive Fluzone Quadrivalent during pregnancy in Sanofi Pasteur Inc.'s vaccination pregnancy registry by calling 1-800-822-2463.
It is not known whether Fluzone Quadrivalent is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Fluzone Quadrivalent is administered to a nursing woman.
Safety and effectiveness of Fluzone Quadrivalent in children below the age of 6 months have not been established.
Safety and immunogenicity of Fluzone Quadrivalent were evaluated in adults 65 years of age and older. [See Clinical Studies] Antibody responses to Fluzone Quadrivalent are lower in persons ≥ 65 years of age than in younger adults.
REFERENCES
1 Lasky T, Terracciano GJ, Magder L, et al. The Guillain-Barré syndrome and the 1992-1993 and 1993-1994 influenza vaccines. N Engl J Med 1998;339:1797-802.
No information provided.
Do not administer Fluzone Quadrivalent to anyone with a history of a severe allergic reaction (e.g., anaphylaxis) to any component of the vaccine [see DESCRIPTION], including egg protein, or to a previous dose of any influenza vaccine.
Influenza illness and its complications follow infection with influenza viruses. Global surveillance of influenza identifies yearly antigenic variants. Since 1977, antigenic variants of influenza A (H1N1 and H3N2) viruses and influenza B viruses have been in global circulation. Since 2001, two distinct lineages of influenza B (Victoria and Yamagata lineages) have cocirculated worldwide. Protection from influenza virus infection has not been correlated with a specific level of hemagglutination inhibition (HI) antibody titer post-vaccination. However, in some human studies, antibody titers ≥ 1:40 have been associated with protection from influenza illness in up to 50% of subjects. (See ref. 2) (See ref. 3)
Antibodies against one influenza virus type or subtype confer limited or no protection against another. Furthermore, antibodies to one antigenic variant of influenza virus might not protect against a new antigenic variant of the same type or subtype. Frequent development of antigenic variants through antigenic drift is the virologic basis for seasonal epidemics and the reason for the usual change of one or more new strains in each year’s influenza vaccine. Therefore, influenza vaccines are standardized to contain the hemagglutinins of influenza virus strains representing the influenza viruses likely to be circulating in the US during the influenza season. Annual vaccination with the influenza vaccine is recommended because immunity during the year after vaccination declines and because circulating strains of influenza virus change from year to year.
The effectiveness of Fluzone Quadrivalent was demonstrated based on clinical endpoint efficacy data for Fluzone (trivalent influenza vaccine) and on an evaluation of serum HI antibody responses to Fluzone Quadrivalent. Fluzone Quadrivalent, an inactivated influenza vaccine that contains the hemagglutinins of two influenza A subtype viruses and two influenza type B viruses, is manufactured according to the same process as Fluzone.
A randomized, double-blind, placebo-controlled study was conducted at a single US center during the 1999-2000 (Year 1) and 2000-2001 (Year 2) influenza seasons. The intent-totreat analysis set included a total of 786 children 6 through 24 months of age. Participants received two doses of either Fluzone (N = 525) or a placebo (N = 261). Among all randomized participants in both years, the mean age was 13.8 months; 52.5% were male, 50.8% were Caucasian, 42.0% were Black, and 7.2% were of other racial groups. Cases of influenza were identified through active and passive surveillance for influenza-like illness or acute otitis media and confirmed by culture. Influenza-like illness was defined as fever with signs or symptoms of an upper respiratory infection. Vaccine efficacy against all influenza viral types and subtypes was a secondary endpoint and is presented in Table 7.
Table 7: Estimated Efficacy of Fluzone (Trivalent
Influenza Vaccine) Against Culture- Confirmed Influenza in Children Aged 6
through 24 Months during the 1999-2000 and 2000-2001 Influenza Seasons - Intent-to-Treat
Analysis Seta
| Year | Fluzoneb | Placeboc | Fluzone vs. Placebo | |||||||
| nd | Ne | Rate (n/N)f | (95% CI) | nd | Ne | Rate (n/N)f | (95% CI) | Relative Risk (95% CI) | Percent Relative Reductions (95% CI) | |
| Year 1h (1999-2000) | 15 | 273 | 5.5 | (3.1; 8.9) | 22 | 138 | 15.9 | (10.3; 23.1) | 0.34 (0.18; 0.64) | 66 (36; 82) |
| Year 2i(2000-2001) | 9 | 252 | 3.6 | (1.6; 6.7) | 4 | 123 | 3.3 | (0.9; 8.1) | 1.10 (0.34; 3.50) | -10 (-250; 66) |
| aThe intent-to-treat analysis set includes all
enrolled participants who were randomly assigned to receive Fluzone or placebo
and vaccinated bFluzone: 1999-2000 formulation containing A/Beijing/262/95 (H1N1), A/Sydney/15/97 (H3N2), and B/Yamanashi/166/98 (Yamagata lineage) and 2000-2001 formulation containing A/New Caledonia/20/99 (H1N1), A/Panama/2007/99 (H3N2), and B/Yamanashi/166/98 (Yamagata lineage) cPlacebo: 0.4% NaCl dn is the number of participants with culture-confirmed influenza for the given year of study as listed in the first column eN is the number of participants randomly assigned to receive Fluzone or placebo for the given year of study as listed in the column headers (intent-to-treat analysis set) fRate (%) = (n/N) * 100 gRelative reduction in vaccine efficacy was defined as (1-relative risk) x 100 hIncludes all culture confirmed influenza cases throughout the study duration for Year 1 (12 months of follow-up) iIncludes all culture-confirmed influenza cases throughout the study duration for Year 2 (6 months of follow-up) |
||||||||||
A randomized, double-blind, placebo-controlled study was conducted in a single US center during the 2007-2008 influenza season. Participants received one dose of either Fluzone vaccine (N=813), an active comparator (N = 814), or placebo (N = 325). The intent-to-treat analysis set included 1138 healthy adults who received Fluzone or placebo. Participants were 18 through 49 years of age (mean age was 23.3 years); 63.3% were female, 83.1% were Caucasian, and 16.9% were of other racial/ethnic groups. Cases of influenza were identified through active and passive surveillance and confirmed by cell culture and/or real-time polymerase chain reaction (PCR). Influenza-like illness was defined as an illness with at least 1 respiratory symptom (cough or nasal congestion) and at least 1 constitutional symptom (fever or feverishness, chills, or body aches). Vaccine efficacy of Fluzone against all influenza viral types and subtypes is presented in Table 8.
Table 8: Estimated Efficacy of Fluzone (Trivalent
Influenza Vaccine) Against Influenza in Adults Aged 18 through 49 Years during
the 2007-2008 Influenza Season - Intent-to-Treat Analysis Setab
| Laboratory-Confirmed Symptomatic Influenza | Fluzonec (N=813)e |
Placebod (N=325)e |
Fluzone vs. | Placebo | ||||
| nf | Rate (%)g | (95% CI) | nf | Rate (%)g | (95% CI) | Relative Risk (95% CI) | Percent Relative Reductionh(95% CI) | |
| Positive culture | 21 | 2.6 | (1.6; 3.9) | 31 | 9.5 | (6.6; 13.3) | 0.27 (0.16; 0.46) | 73 (54; 84) |
| 28 | 3.4 | (2.3; 4.9) | 35 | 10.8 | (7.6: 14.7) | 0.32 (0.20; 0.52) | 68 (48; 80) | |
| Positive culture, positive PCR, or both | 28 | 3.4 | (2.3; 4.9) | 35 | 10.8 | (7.6; 14.7) | 0.32 (0.20; 0.52) | 68 (48; 80) |
| aNCT00538512 bThe intent-to-treat analysis set includes all enrolled participants who were randomly assigned to receive Fluzone or placebo and vaccinated cFluzone: 2007-2008 formulation containing A/Solomon Islands/3/2006 (H1N1), A/Wisconsin/67/2005 (H3N2), and B/Malaysia/2506/2004 (Victoria lineage) dPlacebo: 0.9% NaCl eN is the number of participants randomly assigned to receive Fluzone or placebo fn is the number of participants satisfying the criteria listed in the first column gRate (%) = (n/N) * 100 hRelative reduction in vaccine efficacy was defined as (1 - relative risk) x 100 |
||||||||
In Study 1 (NCT01240746) [see ADVERSE REACTIONS], 1419 children 6 months through 35 months of age and 2101 children 3 years through 8 years of age were included in the per-protocol immunogenicity analysis. Participants received one or two 0.25 mL doses or one or two 0.5 mL doses, respectively of Fluzone Quadrivalent, TIV-1, or TIV-2. For participants who received two doses, the doses were administered approximately 4 weeks apart. The distribution of demographic characteristics was similar to that of the safety analysis [see ADVERSE REACTIONS].
HI antibody geometric mean titers (GMTs) and seroconversion rates 28 days following vaccination with Fluzone Quadrivalent were non-inferior to those following each TIV for all four strains, based on pre-specified criteria (see Table 9 and Table 10).
Table 9: Study 1a: Non-inferiority of
Fluzone Quadrivalent Relative to TIV for Each Strain by HI Antibody GMTs at 28
Days Post-Vaccination, Persons 6 Months Through 8 Years of Age (Per-protocol
Analysis Set)b
| Antigen Strain | Fluzone Quadrivalentc Nd=2339 |
Pooled TIVe Nd=1181 |
GMT Ratio (95% CI)f | |
| GMT | GMT | |||
| A (H1N1) | 1124 | 1096 | 1.03 (0.93; 1.14) |
|
| A (H3N2) | 822 | 828 | 0.99 (0.91; 1.08) |
|
| Fluzone Quadrivalentc Nd=2339 |
TIV-1 g (B Victoria) Nd=582 |
TIV-2h (B Yamagata) Nd=599 |
GMT Ratio (95% CI)f | |
| GMT | GMT | GMT | ||
| B/Brisbane/60/2008 (B Victoria) | 86.1 | 64.3 | (19.5)1 | 1.34 (1.20; 1.50) |
| B/Florida/04/2006 (B Yamagata) | 61.5 | (16.3)i | 58.3 | 1.06 (0.94; 1.18) |
| aNCT01240746 bPer-protocol analysis set included all persons who had no study protocol deviations cFluzone Quadrivalent containing A/California/07/2009 (H1N1), A/Victoria/210/2009 (H3N2), B/ Brisbane/60/2008 (Victoria lineage), and B/Florida/04/2006 (Yamagata lineage) dN is the number of participants in the per-protocol analysis set ePooled TIV group includes participants vaccinated with either TIV-1 or TIV-2 fNon-inferiority was demonstrated if the lower limit of the 2-sided 95% CI of the ratio of GMTs (Fluzone Quadrivalent divided by pooled TIV for the A strains, or the TIV containing the corresponding B strain) was > 0.66 g2010-2011 Fluzone TIV containing A/California/07/2009 (H1N1), A/Victoria/210/2009 (H3N2), and B/Brisbane/60/2008 (Victoria lineage), licensed hInvestigational TIV containing A/California/07/2009 (H1N1), A/Victoria/210/2009 (H3N2), andB/Florida/04/2006 (Yamagata lineage), non-licensed iTIV-2 did not contain B/Brisbane/60/2008 jTIV-1 did not contain B/Florida/04/2006 |
||||
Table 10: Study 1a: Non-inferiority of
Fluzone Quadrivalent Relative to TIV for Each Strain by Seroconversion Rates at
28 Days Post-Vaccination, Persons 6 Months Through 8 Years of Age (Per-protocol
Analysis Set)b
| Antigen Strain | Fluzone Quadrivalentc Nd=2339 |
Pooled
TIVe Nd=1181 |
Difference of Seroconversion Rates (95% CI)g |
|
| Seroconversionf (%) | ||||
| A (H1N1) | 92.4 | 91.4 | 0.9 (-0.9; 3.0) | |
| A (H3N2) | 88.0 | 84.2 | 0.9 (-0.9; 3.0) | |
| Fluzone Quadrivalentc Nd=2339 |
TIV-1h (B Victoria) Nd=582 |
TIV-2i (B Yamagata) Nd=599 |
Difference of Seroconversion Rates (95% CI)g | |
| Seroconversionf(%) | ||||
| B/Brisbane/60/2008 (B Victoria) | 71.8 | 61.1 | (20.0)j | 10.7 (6.4; 15.1) |
| B/Florida/04/2006 (B Yamagata) | 66.1 | (17.9)k | 64.0 | 2.0 (-2.2; 6.4) |
| aNCT01240746 bPer-protocol analysis set included all persons who had no study protocol deviations cFluzone Quadrivalent containing A/California/07/2009 (H1N1), A/Victoria/210/2009 (H3N2), B/Brisbane/60/2008 (Victoria lineage), and B/Florida/04/2006 (Yamagata lineage) dN is the number of participants in the per-protocol analysis set ePooled TIV group includes participants vaccinated with either TIV-1 or TIV-2 fSeroconversion: Paired samples with pre-vaccination HI titer < 1:10 and post-vaccination titer ≥ 1:40 or a minimum 4-fold increase for participants with pre-vaccination titer ≥ 1:10 gNon-inferiority was demonstrated if the lower limit of the 2-sided 95% CI of the difference in seroconversion rates (Fluzone Quadrivalent minus pooled TIV for the A strains, or the TIV containing the corresponding B strain) was > -10% h2010-2011 Fluzone TIV containing A/California/07/2009 (H1N1), A/Victoria/210/2009 (H3N2), and B/Brisbane/60/2008 (Victoria lineage), licensed iInvestigational TIV containing A/California/07/2009 (H1N1), A/Victoria/210/2009 (H3N2), and B/ Florida/04/2006 (Yamagata lineage), non-licensed jTIV-2 did not contain B/Brisbane/60/2008 kTIV-1 did not contain B/Florida/04/2006 |
||||
Non-inferiority immunogenicity criteria based on HI antibody GMTs and seroconversion rates were also met when age subgroups (6 months to < 36 months and 3 years to < 9 years) were examined. In addition, HI antibody GMTs and seroconversion rates following Fluzone Quadrivalent were higher than those following TIV for the B strain not contained in each respective TIV based on pre-specified criteria (the lower limit of the 2-sided 95% CI of the ratio of the GMTs [Fluzone Quadrivalent divided by TIV] > 1.5 for each B strain in Fluzone Quadrivalent compared with the corresponding B strain not contained in each TIV and the lower limit of the two 2-sided 95% CI of the difference of the seroconversion rates [Fluzone Quadrivalent minus TIV] > 10% for each B strain in Fluzone Quadrivalent compared with the corresponding B strain not contained in each TIV).
In Study 2 (NCT00988143) [see ADVERSE REACTIONS], 565 adults 18 years of age and older who had received one dose of Fluzone Quadrivalent, TIV-1, or TIV-2 were included in the perprotocol immunogenicity analysis. The distribution of demographic characteristics was similar to that of the safety analysis [see ADVERSE REACTIONS].
HI antibody GMTs 21 days following vaccination with Fluzone Quadrivalent were non-inferior to those following each TIV for all four strains, based on pre-specified criteria (see Table 11).
Table 11: Study 2a: Non-inferiority of
Fluzone Quadrivalent Relative to TIV for Each Strain by HI Antibody GMTs at 21
Days Post-Vaccination, Adults 18 Years of Age and Older (Per-protocol Analysis
Set)b
| Antigen Strain | Fluzone Quadrivalentc Nd=190 |
Pooled TIVe Nd=375 |
GMT Ratio (95% CI)f | |
| GMT | GMT | |||
| A (H1N1) | 161 | 151 | 1.06 (0.87; 1.31) |
|
| A (H3N2) | 304 | 339 | 0.90 (0.70; 1.15) |
|
| Fluzone Quadrivalentc Nd=190 |
TIV-1g (B Victoria) Nd=187 |
TIV-2h (B Yamagata) Nd=188 |
GMT Ratio (95% CI)f | |
| GMT | GMT | GMT | ||
| B/Brisbane/60/2008 (B Victoria) | 101 | 114 | (44.0)1 | 0.89 (0.70; 1.12) |
| B/Florida/04/2006 (B Yamagata) | 155 | (78.1)j | 135 | 1.15 (0.93; 1.42) |
| aNCT00988143 bPer-protocol analysis set included all persons who had no study protocol deviations cFluzone Quadrivalent containing A/Brisbane/59/2007 (H1N1), A/Uruguay/716/2007 (H3N2), B/Brisbane/60/2008 (Victoria lineage), and B/Florida/04/2006 (Yamagata lineage) dN is the number of participants in the per-protocol analysis set ePooled TIV group includes participants vaccinated with either TIV-1 or TIV-2 fNon-inferiority was demonstrated if the lower limit of the 2-sided 95% CI of the ratio of GMTs (Fluzone Quadrivalent divided by pooled TIV for the A strains, or the TIV containing the corresponding B strain) was > 2/3 g2009-2010 Fluzone TIV containing A/Brisbane/59/2007 (H1N1), A/Uruguay/716/2007 (H3N2), and B/Brisbane/60/2008 (Victoria lineage), licensed h2008-2009 Fluzone TIV containing A/Brisbane/59/2007 (H1N1), A/Uruguay/716/2007 (H3N2), and B/Florida/04/2006 (Yamagata lineage), licensed iTIV-2 did not contain B/Brisbane/60/2008 jTIV-1 did not contain B/Florida/04/2006 |
||||
In Study 3 (NCT01218646) [see ADVERSE REACTIONS], 660 adults 65 years of age and older were included in the per-protocol immunogenicity analysis. The distribution of demographic characteristics was similar to that of the safety analysis [see ADVERSE REACTIONS].
HI antibody GMTs 21 days following vaccination with Fluzone Quadrivalent were non-inferior to those following TIV for all four strains, based on pre-specified criteria (see Table 12). Seroconversion rates 21 days following Fluzone Quadrivalent were non-inferior to those following TIV for H3N2, B/Brisbane, and B/Florida, but not for H1N1 (see Table 13). The HI antibody GMT following Fluzone Quadrivalent was higher than that following TIV-1 for B/Florida but not higher than that following TIV-2 for B/Brisbane, based on pre-specified criteria (the lower limit of the 2-sided 95% CI of the ratio of the GMTs [Fluzone Quadrivalent divided by TIV] > 1.5 for each B strain in Fluzone Quadrivalent compared with the corresponding B strain not contained in each TIV). Seroconversion rates following Fluzone Quadrivalent were higher than those following TIV for the B strain not contained in each respective TIV, based on pre-specified criteria (the lower limit of the two 2-sided 95% CI of the difference of the seroconversion rates [Fluzone Quadrivalent minus TIV] > 10% for each B strain in Fluzone Quadrivalent compared with the corresponding B strain not contained in each TIV).
Table 12: Study 3a: Non-inferiority of
Fluzone Quadrivalent Relative to TIV for Each Strain by HI Antibody GMTs at 21
Days Post-Vaccination, Adults 65 Years of Age and Older (Per-protocol Analysis
Set)b
| Antigen Strain | Fluzone Quadrivalentc Nd=220 |
Pooled TIVe Nd=440 |
GMT Ratio (95% CI)f | |
| GMT | GMT | |||
| A (H1N1) | 231 | 270 | 0.85 (0.67; 1.09) |
|
| A (H3N2) | 501 | 324 | 1.55 (1.25; 1.92) |
|
| Fluzone Quadrivalentc Nd=220 |
TIV-19 (B Victoria) Nd=219 |
TIV-2h (B Yamagata) Nd=221 |
GMT Ratio (95% CI)f | |
| GMT | GMT | GMT | ||
| B/Brisbane/60/2008 (B Victoria) | 73.8 | 57.9 | (42.2)i | 1.27 (1.05; 1.55) |
| B/Florida/04/2006 (B Yamagata) | 61.1 | (28.5)j | 54.8 | 1.11 (0.90; 1.37) |
| aNCT01218646 bPer-protocol analysis set included all persons who had no study protocol deviations cFluzone Quadrivalent containing A/California/07/2009 (H1N1), A/Victoria/210/2009 (H3N2), B/Brisbane/60/2008 (Victoria lineage), and B/Florida/04/2006 (Yamagata lineage) dN is the number of participants in the per-protocol analysis set ePooled TIV group includes participants vaccinated with either TIV-1 or TIV-2 fNon-inferiority was demonstrated if the lower limit of the 2-sided 95% CI of the ratio of GMTs (Fluzone Quadrivalent divided by pooled TIV for the A strains, or the TIV containing the corresponding B strain) was > 0.66 g2010-2011 Fluzone TIV containing A/California/07/2009 (H1N1), A/Victoria/210/2009 (H3N2), and B/Brisbane/60/2008 (Victoria lineage), licensed hInvestigational TIV containing A/California/07/2009 (H1N1), A/Victoria/210/2009 (H3N2), and B/Florida/04/2006 (Yamagata lineage), non-licensed iTIV-2 did not contain B/Brisbane/60/2008 jTIV-1 did not contain B/Florida/04/2006 |
||||
Table 13: Study 3a: Non-inferiority of
Fluzone Quadrivalent Relative to TIV for Each Strain by Seroconversion Rates at
21 Days Post-Vaccination, Adults 65 Years of Age and Older (Per-protocol
Analysis Set)b
| Antigen Strain | Fluzone Quadrivalentc Nd=220 |
Pooled TIVe Nd=440 |
Difference of Seroconversion Rate (95% CI)f | |
| Seroconversiong(%) | ||||
| A (H1N1) | 65.91 | 69.77 | -3.86 (-11.50; 3.56) | |
| A (H3N2) | 69.09 | 59.32 | 9.77 (1.96; 17.20) | |
| Fluzone Quadrivalentc Nd=220 |
TIV-1h (B Victoria) Nd=219 |
TIV-2i(B Yamagata) Nd=221 |
Difference of Seroconversion Rate (95% CI)f | |
| SeroconversionS(%) | ||||
| B/Brisbane/60/2008 (B Victoria) | 28.64 | 18.72 | (8.60)j | 9.91 (1.96; 17.70) |
| B/Florida/04/2006 (B Yamagata) | 33.18 | (9.13)k | 31.22 | 1.96 (-6.73; 10.60) |
| aNCT01218646 bPer-protocol analysis set included all persons who had no study protocol deviations cFluzone Quadrivalent containing A/California/07/2009 (H1N1), A/Victoria/210/2009 (H3N2), B/Brisbane/60/2008 (Victoria lineage), and B/Florida/04/2006 (Yamagata lineage) dN is the number of participants in the per-protocol analysis set ePooled TIV group includes participants vaccinated with either TIV-1 or TIV-2 fNon-inferiority was demonstrated if the lower limit of the 2-sided 95% CI of the difference in seroconversion rates (Fluzone Quadrivalent minus pooled TIV for the A strains, or the TIV containing the corresponding B strain) was > -10% gSeroconversion: Paired samples with pre-vaccination HI titer < 1:10 and post-vaccination titer ≥ 1:40 or a minimum 4-fold increase for participants with pre-vaccination titer ≥ 1:10 h2010-2011 Fluzone TIV containing A/California/07/2009 (H1N1), A/Victoria/210/2009 (H3N2), and B/Brisbane/60/2008 (Victoria lineage), licensed iInvestigational TIV containing A/California/07/2009 (H1N1), A/Victoria/210/2009 (H3N2), and B/ Florida/04/2006 (Yamagata lineage), non-licensed jTIV-2 did not contain B/Brisbane/60/2008 kTIV-1 did not contain B/Florida/04/2006 |
||||
REFERENCES
2 Hannoun C, Megas F, Piercy J. Immunogenicity and
protective efficacy of influenza vaccination. Virus Res 2004;103:133-138.
3 Hobson D, Curry RL, Beare AS, Ward-Gardner A. The role
of serum haemagglutinationinhibiting antibody in protection against challenge
infection with influenza A2 and B viruses. J Hyg Camb 1972;70:767-777.
No information provided. Please refer to the WARNINGS AND PRECAUTIONS sections.
